Multisystem Cell Therapy for Improvement of Urinary Continence

Urinary Stress Incontinence Clinical Trial

— MUSIC  

Official title:

Open-label, Monocentric, First-in-man Trial to Assess Safety and Tolerability of a New Therapeutic Strategy for Stress Urinary Incontinence Based on the Implantation of Muscle Precursor Cells (MPCs)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03439527
• Other study ID #: H2020-SC1-2016-2017
• Secondary ID: 731377
• Status: Completed
• Phase: Phase 1
• Start date: January 22, 2020
• Est. completion date: October 21, 2021

Study information

• Verified date: October 2021
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The rising success of cell therapies places an increasing burden on health care costs. Consequently, the need to reduce production costs while maintaining quality has been widely acknowledged. In addition, the demand for high-quality products with an optimal safety profile is increasing. The proposed cell treatment is the first therapeutical option with the possibility to revert the underlying condition. The investigators expect that this healing response will be achieved with minimal side effects justifying the addional costs and complexity.

Description:

muscle precursor cells (MPCs) will be isolated from biopsies of the lower leg of patients, seeded, expanded and cultivated in vitro in a GMP facility to generate vital muscle cells dedicated for implantation. These muscle cells exhibit myogenic phenotype (IHC and flow cytometry) and therefore morphological and histological prerequisites approximating the properties of native skeletal muscle tissue. The muscle progenitor cells shall be applied in external sphincter muscle for the treatment of patients with stress urinary incontinence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: October 21, 2021
• Est. primary completion date: September 3, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

Adult women 20y-60y

• Incontinence >/= grade I since at least 6 months
• Predominant clinical diagnosis of SUI
• Candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons).
• Post void residual volume of <100 ml (exclusion of overflow incontinence)
• Can independently use toilet without difficulty
• Capacity to answer the questionnaires of evaluation
• Negative blood test for: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C Anti-HCV-Ab, Syphilis
• Competent to comprehend, sign and date informed consent form before any study-specific procedure is performed

Exclusion Criteria:

• History of anti-incontinence or prolapse surgery.
• Previous diagnosis of any of the following conditions, disorders, or diseases of the

urinary tract:

• Clinically significant cystocele or rectocele
• Ureteric bladder, urethral or rectal fistula
• Uncorrected congenital abnormality leading to urinary incontinence
• Interstitial cystitis
• Urinary urgency that results in leakage (as a predominant symptom)
• Adult enuresis
• Urodynamically proven detrusor instability
• Sensory urgency defined as first sensation of bladder fill (urge to void) of <100 ml; bladder capacity of <300 ml
• No sensation at any time during the simple filling cystometry procedure
• Known urethral stenosis (ureterocystoscopy) or urethral diverticulum
• History of urogenital cancer or history of pelvic radiotherapy
• Women who are pregnant, breast feeding or <12 months postpartum Note: Female subjects who are surgically sterilized, hysterectomized or post-menopausal for longer than 2 years are not considered as having child bearing potential. No pregnancy test will be performed for this population.
• Untreated symptomatic urinary tract infection
• Fever (as defined by = 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days
• Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment
• Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.
• Known allergy or intolerance of at least one of the active ingredients or excipients of the investigational products
• Known allergy or intolerance of Penicillin or Streptomycin
• Known genetically determined or acquired muscular disease.
• Known Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism).
• Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study.
• Chronic use of any of the following drugs and not stopped for at least 2 weeks prior to inclusion into the study: selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs.
• Chronic use of any of the following drugs and not stopped for at least 6 months prior to inclusion into the study: Antidepressants or neuroleptic drugs.

Related Conditions & MeSH terms

• Urinary Incontinence, Stress
• Urinary Stress Incontinence

Intervention

Other:
• Muscle Precursor Cells (MPCs), ATMP
The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zürich

Sponsors (3)

Lead Sponsor	Collaborator
University of Zurich	Salzburger Landeskliniken, University Hospital Tuebingen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of clinically relevant Adverse Events of MPCs or related to cell injection	Number of clinically relevant findings related to cell injection	at 3 months post-implantation
Secondary	Feasibility of MPC injection	Percentage of subjects with successful injection	day of implantation
Secondary	Efficacy of MPC injection measured by post-void residual volume	post-void residual volume	at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation
Secondary	Efficacy of MPC injection measured by Uroflowmetry	Uroflowmetry: urinary flow pattern	at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation
Secondary	Efficacy of MPC injection measured by Urodynamic Evaluation	2 Filling-Cystometries	at baseline, 3 months and 6 months post-implantation
Secondary	Efficacy of MPC injection measured by Urodynamic Evaluation	2 Pressure-Flow studies	at baseline, 3 months and 6 months post-implantation
Secondary	Efficacy of MPC injection measured by Urodynamic Evaluation	Urethal-Pressure-Profile	at baseline, 3 months and 6 months post-implantation
Secondary	Efficacy of MPC injection measured by 1h pad test	1h pad test	at baseline, 1 month, 3 months and 6 months post-implantation
Secondary	Efficacy measured by average Incontinence Score	Incontinence Score. Range from 0 (no incentinence) to 21 (highly incontinent)	at baseline, 1 month, 3 months and 6 months post-implantation
Secondary	Efficacy measured by average score of Visual Analog Scale of degree of suffering	Visual Analog Scale of degree of suffering. Range 0 (worst) to 10 (best)	at baseline, 1 month, 3 months and 6 months post-implantation
Secondary	Efficacy measured by average score of Quality of Life	Quality of Life Score, using SF-36v2™ Health Survey	at baseline, 1 month, 3 months and 6 months post-implantation
Secondary	Efficacy	Number for (planned) subsequent incontinence surgery	6 months post-implantation
Secondary	Number of patients with abnormal laboratory values and/or Adverse Events that are related to MPC injection	Safety measures (ultrasound, physical examination, laboratroy)	at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation